(Total Views: 540)
Posted On: 01/27/2025 8:32:33 AM
Post# of 149955
Agenus' botensilimab/balstilimab combination data in CRC presented at ASCO GI. "Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings."
A number of these studies are investigator sponsored. After Agenus showed some promising data in MSS mCRC, it seems interest was piqued and studies run in various settings.
Interestingly, even Stingray Therapeutics recently initiated an open label phase 2 trial with their oral ENPP1 inhibitor in combination with BOT/BAL in refractory MSS mCRC.
Can't wait for our turn when investigators and companies are clamoring to run trials with leronlimab.
https://investor.agenusbio.com/news/news-deta...fault.aspx
A number of these studies are investigator sponsored. After Agenus showed some promising data in MSS mCRC, it seems interest was piqued and studies run in various settings.
Interestingly, even Stingray Therapeutics recently initiated an open label phase 2 trial with their oral ENPP1 inhibitor in combination with BOT/BAL in refractory MSS mCRC.
Can't wait for our turn when investigators and companies are clamoring to run trials with leronlimab.
https://investor.agenusbio.com/news/news-deta...fault.aspx
(4)
(0)Scroll down for more posts ▼
